Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?-Reference-Cited by-同舟云学术

Can dysplasia surveillance be better targeted in ulcerative colitis by using faecal calprotectin?

Published:2022-06-13 Issue:11 Volume:57 Page:1304-1311
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Puolanne Anna-Maija¹,Qadri Sami¹²,Vesterinen Tiina³^ORCID,Hiltunen Saara⁴,Mustonen Aaro⁵,Kurki Samu⁶,Kolho Kaija-Leena⁷⁸,Arola Johanna³,Färkkilä Martti¹^ORCID

Affiliation:

1. Department of Gastroenterology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

2. Minerva Foundation Institute for Medical Research, Helsinki, Finland

3. Department of Pathology, HUS Diagnostic Centre, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

4. BCB Medical Ltd., Data Analyst, Data and Analytics, Espoo, Finland

5. BCB Medical Ltd., Real World Data Manager, Life Science, Scientific Medical Content and Project Management, Espoo, Finland

6. Institute for Molecular Medicine FIMM, University of Helsinki and Abdominal Centre, Endocrinology, Helsinki University Hospital, Helsinki, Finland

7. Children’s Hospital, Helsinki University and Helsinki University Hospital, Helsinki, Finland

8. Tampere University, Tampere, Finland

Funder

the Mary and George Ehrnrooth’s Foundation

the Helsinki University Hospital Research

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://www.tandfonline.com/doi/pdf/10.1080/00365521.2022.2084345

Reference33 articles.

1. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: A case-control observational study based on registry data

2. Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies

3. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis

4. Colorectal cancer prevention in patients with ulcerative colitis

5. Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease